Genome Editing on Human Embryos: US Startups Push Ethical Boundaries

Several startups in the United States are now exploring genome editing in human embryos, a scientific frontier that raises serious ethical questions. These companies aim to modify DNA in the earliest stages of human development, potentially preventing inherited genetic diseases. However, the practice is not yet approved for clinical use and remains highly controversial. Critics argue that altering human embryos crosses a moral line, as changes would be passed down to future generations. Proponents say the technology could eliminate devastating conditions before birth. As research advances, regulators and scientists face growing pressure to define clear boundaries.